Brainomix AI Imaging Chosen as Co-Primary Endpoint in Landmark Pulmonary Fibrosis Trial
AI is quietly reshaping clinical trials—and not just by speeding up drug discovery. In a notable milestone for medical imaging and respiratory research, Brainomix has been selected by Boehringer Ingelheim to provide AI-powered imaging biomarkers as a co-primary endpoint in a Phase 3 pulmonary fibrosis study.
